Literature DB >> 23321328

Efficient plasmid-mediated gene transfection of ovine bone marrow mesenchymal stromal cells.

Paola Locatelli1, Fernanda Daniela Olea, Anna Hnatiuk, Diana Sepúlveda, Juan Manuel Pérez Sáez, Rafael Argüello, Alberto Crottogini.   

Abstract

BACKGROUND AIMS: Given the close similarity between ovine and human cardiomyocytes, sheep models of myocardial infarction and heart failure are increasingly used in studies of stem cell-mediated heart regeneration. In these studies, mesenchymal stromal cells (MSCs) are frequently employed. To enhance the paracrine effects of these MSCs, ex vivo transfection with genes encoding growth factors has been proposed. Although viral vectors exhibit higher transfection efficiency than plasmids, they entail the risks of uncontrolled transgene expression and immune reactions that preclude repeated administration. Our aim was to optimize the efficiency of plasmid-mediated transfection of ovine MSCs, while preserving cell viability.
METHODS: Varying amounts of diverse cationic lipids were used to obtain the reagent-to-DNA mass ratio showing highest luciferase activity. Transfection efficiency (flow cytometry) was tested on plasmid-green fluorescent protein-transfected MSCs at increasing DNA mass.
RESULTS: Lipofectamine LTX 5 μL and Plus reagent 4 μL with 2 μg of DNA yielded 42.3 ± 4.7% transfection efficiency, while preserving cell viability. Using these transfection conditions, we transfected MSCs with a plasmid encoding human vascular endothelial growth factor (VEGF) and found high VEGF protein concentrations in the culture supernatant from day 2 (1968 ± 324 pg/mL per μg DNA) through at least day 12 (888 ± 386 pg/mL per μg DNA) after transfection.
CONCLUSIONS: Plasmid-mediated transfection of ovine MSCs to over-express paracrine heart-regenerative growth factors is feasible and efficient and overcomes the risks and limitations associated with the use of viral vectors.
Copyright © 2013 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23321328     DOI: 10.1016/j.jcyt.2012.11.004

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  5 in total

1.  Mesenchymal stromal cells overexpressing vascular endothelial growth factor in ovine myocardial infarction.

Authors:  P Locatelli; F D Olea; A Hnatiuk; A De Lorenzi; M Cerdá; C S Giménez; D Sepúlveda; R Laguens; A Crottogini
Journal:  Gene Ther       Date:  2015-03-19       Impact factor: 5.250

2.  Optimizing Lipofectamine LTX Complex and G-418 Concentration for Improvement of Transfection Efficiency in Human Mesenchymal Stem Cells.

Authors:  Taghavi M; Parham A; Dehghani H; Naderi-Meshkin H
Journal:  Arch Razi Inst       Date:  2021-11-30

Review 3.  Gene therapy for bone engineering.

Authors:  Elizabeth Rosado Balmayor; Martijn van Griensven
Journal:  Front Bioeng Biotechnol       Date:  2015-02-02

4.  Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer.

Authors:  Yujuan Zhang; Donghong Zhang; Fei Wang; Danfei Xu; Ye Guo; Wei Cui
Journal:  Sci Rep       Date:  2015-12-14       Impact factor: 4.379

Review 5.  Transplanting Mesenchymal Stem Cells for Treatment of Ischemic Stroke.

Authors:  Fan Wang; Hailiang Tang; Jianhong Zhu; John H Zhang
Journal:  Cell Transplant       Date:  2018-09-25       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.